Section

SPR® Therapeutics Announces Extensive Set of Abstracts to be Shared at North American Neuromodulation Society (NANS) Annual Meeting 2024

Retrieved on: 
Tuesday, January 16, 2024

CLEVELAND, Jan. 16, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc. will be featured prominently at the North American Neuromodulation Society (NANS) Annual Meeting January 18-21 in Las Vegas.

Key Points: 
  • CLEVELAND, Jan. 16, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc. will be featured prominently at the North American Neuromodulation Society (NANS) Annual Meeting January 18-21 in Las Vegas.
  • A total of 11 abstracts highlighting applications of the SPRINT® PNS System will be featured at the meeting including four posters never before presented to the industry.
  • The presentation reviews treatment costs for patients in two cohorts who started treatment either with SPRINT PNS or with a conventional brief PNS trial.
  • The poster reviews health economics and outcomes research to explore the economic implications of the use of SPRINT PNS in chronic low back pain.

Guggenheim Investments Announces January 2024 Closed-End Fund Distributions

Retrieved on: 
Tuesday, January 2, 2024

Final determination of the character of distributions will be made at year-end.

Key Points: 
  • Final determination of the character of distributions will be made at year-end.
  • Distributions may be paid from sources of income other than ordinary income, such as short-term capital gains, long-term capital gains or return of capital.
  • Unless otherwise noted, the distributions above are not anticipated to include a return of capital.
  • The final determination of the source and tax characteristics of all distributions will be made after the end of the year.

CARGO Therapeutics Announces Scientific Advisory Board

Retrieved on: 
Wednesday, December 6, 2023

SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy.

Key Points: 
  • SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy.
  • The SAB will provide strategic counsel and critical expertise as CARGO advances its mission to develop the next generation of transformational CAR T-cell therapies.
  • “The SAB stands out by bringing together several highly accomplished translational investigators each with CAR T-cell experience that bridges both the laboratory and the clinic,” said Robbie Majzner, MD, co-founder of CARGO and Scientific Advisory Board Chair.
  • “They are uniquely suited to advise CARGO on their scientific goals and directions that will lead to better outcomes for patients.”
    Members of the CARGO Scientific Advisory Board are listed below; full bios are available on the CARGO website .

Guggenheim Investments Announces December 2023 Closed-End Fund Distributions

Retrieved on: 
Friday, December 1, 2023

Final determination of the character of distributions will be made at year-end.

Key Points: 
  • Final determination of the character of distributions will be made at year-end.
  • Distributions may be paid from sources of income other than ordinary income, such as short-term capital gains, long-term capital gains or return of capital.
  • Unless otherwise noted, the distributions above are not anticipated to include a return of capital.
  • The final determination of the source and tax characteristics of all distributions will be made after the end of the year.

American Urological Association Announces 2024 Gallagher Health Policy Scholar

Retrieved on: 
Thursday, November 30, 2023

BALTIMORE, Nov. 30, 2023 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is pleased to announce Beth Andersen, MD, FAAP, has been named the 2024 AUA Gallagher Health Policy Scholar.

Key Points: 
  • BALTIMORE, Nov. 30, 2023 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is pleased to announce Beth Andersen, MD, FAAP, has been named the 2024 AUA Gallagher Health Policy Scholar.
  • A highly competitive award, the Gallagher Health Policy Scholar Program is a rigorous year-long training initiative aiming to equip urologists for leadership roles in health policy.
  • Additionally, scholars engage in a week-long health policy seminar for surgeons supported by the American College of Surgeons.
  • “I am honored to be selected as the 2024 AUA Gallagher Health Policy Scholar,” said Dr. Andersen.

FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements

Retrieved on: 
Tuesday, December 19, 2023

The NYSE American Notice has no immediate effect on the listing or trading of the Company’s Class A common stock on NYSE American.

Key Points: 
  • The NYSE American Notice has no immediate effect on the listing or trading of the Company’s Class A common stock on NYSE American.
  • If the NYSE determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the NYSE American Company Guide.
  • The Company intends to regain compliance with the NYSE American continued listing standards.
  • There can be no assurance that the Company will ultimately regain compliance with all applicable NYSE American listing standards.

Music Buzzz Podcast Celebrates 3rd Year and Preps for Season 4, Continuing to Feature Stories You've (Likely) Never Heard Before from Those Who Were There

Retrieved on: 
Wednesday, December 20, 2023

INDIANAPOLIS, Dec. 20, 2023 /PRNewswire-PRWeb/ -- Music Buzzz Podcast launched in 2021 and has featured over 80 episodes of candid discussions with those who are and have been a fly on the wall in the music business including industry veterans representing the segments of Musician, Design and Live. The podcast is hosted by Dane Clark (drummer in the John Mellencamp band since 1996), Hugh Syme (world-renowned graphic artist who has created albums covers for Rush, Dream Theater, Aerosmith, Bon Jovi, Joe Bonamassa, Megadeth, Def Leppard, Kiss, Whitesnake and more) and Andy Wilson (an entertainment executive and President of ELEVATE Entertainment & Event Support Services). Season 3 will wrap up this Friday with episode 82 guest, and legendary bassist, Leland Sklar (The Section, The Immediate Family, James Taylor, Phil Collins and many more) who has played on over 2,000 albums.

Key Points: 
  • Music Buzzz Podcast is hosted by industry veterans including drummer Dane Clark, album cover artist Hugh Syme and live entertainment executive Andy Wilson.
  • Season 4 episodes of Music Buzzz Podcast to feature past & present members of Booker T. & the M.G.
  • "Music Buzzz is a labor of love for the three of us.
  • A library of all Season 1, 2 and 3 episodes is available now.

The Cooper Housing Institute Funds National Study on Housing Choice Vouchers

Retrieved on: 
Wednesday, November 15, 2023

IRVINE, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Today, the Cooper Housing Institute (CHI), a private research foundation dedicated to solving the affordable housing crisis in the U.S., awarded a grant to the nonprofit, nonpartisan RAND Corporation (RAND) to fund research into the Housing Choice Voucher (HCV) program.

Key Points: 
  • IRVINE, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Today, the Cooper Housing Institute (CHI), a private research foundation dedicated to solving the affordable housing crisis in the U.S., awarded a grant to the nonprofit, nonpartisan RAND Corporation (RAND) to fund research into the Housing Choice Voucher (HCV) program.
  • The study will aim to identify actionable steps public housing authorities (PHAs) can take that could lead to improvements in the efficacy and efficiency of this vital affordable housing program.
  • The study aims to identify policy and operational choices within PHA control that could loosen these hurdles and increase voucher utilization.
  • “The housing choice voucher program is a private-public partnership that helps our nation’s low-income families, seniors and veterans afford a safe, decent place to live,” said Will Cooper, Jr., president and co-founder of the Cooper Housing Institute.

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting

Retrieved on: 
Friday, November 10, 2023

WARREN, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two posters recapping the positive data from pharmacokinetic (PK) and pharmacodynamic (PD) pre-clinical and clinical studies of Anaphylm™ (epinephrine) Sublingual Film will be presented at the American College of Allergy Asthma and Immunology (ACAAI) annual meeting, which will be held from November 9-13 in Anaheim, California.

Key Points: 
  • WARREN, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two posters recapping the positive data from pharmacokinetic (PK) and pharmacodynamic (PD) pre-clinical and clinical studies of Anaphylm™ (epinephrine) Sublingual Film will be presented at the American College of Allergy Asthma and Immunology (ACAAI) annual meeting, which will be held from November 9-13 in Anaheim, California.
  • “We are thrilled to have a significant presence at ACAAI this year and are excited to share the positive results from our completed Anaphylm pharmacokinetic and pharmacodynamic studies with leaders in the allergy community,” said Dan Barber, Aquestive’s President and Chief Executive Officer.
  • “These positive results are encouraging as we continue to evaluate the potential of Anaphylm and its ability to provide an important advancement for the treatment of acute allergic reactions, if approved by the FDA.”
    Location: ePoster Section - Exhibit Hall, Monitor 11
    Poster Title: Epinephrine Administered via Sublingual Film, Manual Injection, or Auto-Injectors in Healthy Adults: Pharmacodynamic Results
    Location: ePoster Section - Exhibit Hall, Monitor 11